Pulmonary Aspergillosis: Recent Advances

ABSTRACT

Aspergillosis remains a significant cause of morbidity and mortality. The spectrum of disease is diverse and ranges from noninvasive disease with an excessive immune response, such as in allergic bronchopulmonary aspergillosis (ABPA), to a lack of an immune response as seen in patients with quantitative or qualitative granulocyte deficits and subsequent invasive pulmonary aspergillosis.

Noninvasive diagnostic testing has improved the time to initiation of effective antifungal therapy, and numerous agents in different therapeutic classes are now available as treatment options. Voriconazole remains the preferred agent in the treatment of invasive pulmonary aspergillosis, and recent data have increased interest in the potential of combination therapy against this often lethal infection. The role of host genetics in selecting patients that may benefit from more aggressive antifungal prophylaxis or treatment practices remains unclear but is likely to guide therapeutic choices as newer data become available.

KEYWORDS

Aspergillosis - chronic cavitary aspergillosis - aspergilloma

REFERENCES

• 1 Walsh T J, Anaissie E J, Denning D W Infectious Diseases Society of America et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.  Clin Infect Dis. 2008;  46 (3) 327-360
• 2 Patterson T F, Kirkpatrick W R, White M et al.. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group.  Medicine (Baltimore). 2000;  79 (4) 250-260
• 3 Thompson III G R, Patterson T F. Pulmonary aspergillosis.  Semin Respir Crit Care Med. 2008;  29 (2) 103-110
• 4 Summerbell R. Ascomycetes: Aspergillus, Fusarium, Sporothrix, Piedraia, and their relatives. In: Howard D H, ed. Pathogenic Fungi in Humans and Animals. 2nd ed. New York: Marcel Dekker; 2003: 237-498
• 5 Balajee S A, Houbraken J, Verweij P E et al.. Aspergillus species identification in the clinical setting.  Stud Mycol. 2007;  59 39-46
• 6 Sutton D A, Fothergill A W, Rinaldi M G. Aspergillus in vitro antifungal susceptibility data: new millennium trends. In: Abstracts of Advances Against Aspergillosis, 9–11 September, San Francisco, CA, 2004.  Abstract 16
• 7 Balajee S A, Nickle D, Varga J, Marr K A. Molecular studies reveal frequent misidentification of Aspergillus fumigatus by morphotyping.  Eukaryot Cell. 2006;  5 (10) 1705-1712
• 8 Klich M, Pitt J. A Laboratory Guide to Common Aspergillus Species and Their Teleomorphs. North Ryde, New South Wales, Australia: Commonwealth Scientific and Industrial Research Organization; 1988
• 9 O’Gorman C M, Fuller H T, Dyer P S. Discovery of a sexual cycle in the opportunistic fungal pathogen Aspergillus fumigatus.  Nature. 2009;  457 (7228) 471-474
• 10 Pitt J I, Samson R A. Nomenclatural considerations in naming species of Aspergillus and its teleomorphs.  Stud Mycol. 2007;  59 67-70
• 11 Panackal A A, Li H, Kontoyiannis D P et al.. Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation.  Clin Infect Dis. 2010;  50 (12) 1588-1597
• 12 Portugal R D, Garnica M, Nucci M. Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve.  J Clin Oncol. 2009;  27 (23) 3849-3854
• 13 Patterson J E, Peters J, Calhoon J H et al.. Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients.  Transpl Infect Dis. 2000;  2 (1) 22-28
• 14 Singh N, Paterson D L. Aspergillus infections in transplant recipients.  Clin Microbiol Rev. 2005;  18 (1) 44-69
• 15 Paterson D L, Singh N. Invasive aspergillosis in transplant recipients.  Medicine (Baltimore). 1999;  78 (2) 123-138
• 16 Denning D W. Aspergillosis in “nonimmunocompromised” critically ill patients.  Am J Respir Crit Care Med. 2004;  170 (6) 580-581
• 17 Lat A, Bhadelia N, Miko B, Furuya E Y, Thompson III G R. Invasive aspergillosis after pandemic (H1N1) 2009.  Emerg Infect Dis. 2010;  16 (6) 971-973
• 18 Meersseman W, Vandecasteele S J, Wilmer A, Verbeken E, Peetermans W E, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy.  Am J Respir Crit Care Med. 2004;  170 (6) 621-625
• 19 Warris A, Bjørneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy.  N Engl J Med. 2001;  344 (14) 1099-1100
• 20 Cohen M S, Isturiz R E, Malech H L et al.. Fungal infection in chronic granulomatous disease: the importance of the phagocyte in defense against fungi.  Am J Med. 1981;  71 (1) 59-66
• 21 Gersuk G M, Underhill D M, Zhu L, Marr K A. Dectin-1 and TLRs permit macrophages to distinguish between different Aspergillus fumigatus cellular states.  J Immunol. 2006;  176 (6) 3717-3724
• 22 Hohl T M, Van Epps H L, Rivera A et al.. Aspergillus fumigatus triggers inflammatory responses by stage-specific beta-glucan display.  PLoS Pathog. 2005;  1 (3) e30
• 23 Luther K, Torosantucci A, Brakhage A A, Heesemann J, Ebel F. Phagocytosis of Aspergillus fumigatus conidia by murine macrophages involves recognition by the dectin-1 beta-glucan receptor and Toll-like receptor 2.  Cell Microbiol. 2007;  9 (2) 368-381
• 24 Werner J L, Metz A E, Horn D et al.. Requisite role for the dectin-1 beta-glucan receptor in pulmonary defense against Aspergillus fumigatus.  J Immunol. 2009;  182 (8) 4938-4946
• 25 Chai L Y, de Boer M G, van der Velden W J et al.. The Y238X stop codon polymorphism in the human β-glucan receptor dectin-1 and susceptibility to invasive aspergillosis.  J Infect Dis. 2011;  203 (5) 736-743
• 26 Bochud P Y, Chien J W, Marr K A et al.. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation.  N Engl J Med. 2008;  359 (17) 1766-1777
• 27 Gerson S L, Talbot G H, Hurwitz S, Strom B L, Lusk E J, Cassileth P A. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia.  Ann Intern Med. 1984;  100 (3) 345-351
• 28 Wald A, Leisenring W, van Burik J A, Bowden R A. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation.  J Infect Dis. 1997;  175 (6) 1459-1466
• 29 Denning D W. Invasive aspergillosis.  Clin Infect Dis. 1998;  26 (4) 781-803 quiz 804-805
• 30 Greene R. The radiological spectrum of pulmonary aspergillosis.  Med Mycol. 2005;  43 (Suppl 1) S147-S154
• 31 Caillot D, Couaillier J F, Bernard A et al.. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia.  J Clin Oncol. 2001;  19 (1) 253-259
• 32 Miceli M H, Maertens J, Buvé K et al.. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications.  Cancer. 2007;  110 (1) 112-120
• 33 Baddley J W, Andes D R, Marr K A et al.. Factors associated with mortality in transplant patients with invasive aspergillosis.  Clin Infect Dis. 2010;  50 (12) 1559-1567
• 34 von Eiff M, Roos N, Schulten R, Hesse M, Zühlsdorf M, van de Loo J. Pulmonary aspergillosis: early diagnosis improves survival.  Respiration. 1995;  62 (6) 341-347
• 35 Denning D W, Follansbee S E, Scolaro M, Norris S, Edelstein H, Stevens D A. Pulmonary aspergillosis in the acquired immunodeficiency syndrome.  N Engl J Med. 1991;  324 (10) 654-662
• 36 Kramer M R, Denning D W, Marshall S E et al.. Ulcerative tracheobronchitis after lung transplantation: a new form of invasive aspergillosis.  Am Rev Respir Dis. 1991;  144 (3 Pt 1) 552-556
• 37 Binder R E, Faling L J, Pugatch R D, Mahasaen C, Snider G L. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity.  Medicine (Baltimore). 1982;  61 (2) 109-124
• 38 Gefter W B, Weingrad T R, Epstein D M, Ochs R H, Miller W T. “Semi-invasive” pulmonary aspergillosis: a new look at the spectrum of aspergillus infections of the lung.  Radiology. 1981;  140 (2) 313-321
• 39 Hope W W, Walsh T J, Denning D W. The invasive and saprophytic syndromes due to Aspergillus spp.  Med Mycol. 2005;  43 (Suppl 1) S207-S238
• 40 Denning D W, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review.  Clin Infect Dis. 2003;  37 (Suppl 3) S265-S280
• 41 Felton T W, Baxter C, Moore C B, Roberts S A, Hope W W, Denning D W. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis.  Clin Infect Dis. 2010;  51 (12) 1383-1391
• 42 Muñoz P, Alcalá L, Sánchez Conde M et al.. The isolation of Aspergillus fumigatus from respiratory tract specimens in heart transplant recipients is highly predictive of invasive aspergillosis.  Transplantation. 2003;  75 (3) 326-329
• 43 Horvath J A, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis.  Am J Med. 1996;  100 (2) 171-178
• 44 Herbrecht R, Letscher-Bru V, Oprea C et al.. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients.  J Clin Oncol. 2002;  20 (7) 1898-1906
• 45 Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation.  Blood. 2001;  97 (6) 1604-1610
• 46 Verweij P E, Mennink-Kersten M A. Issues with galactomannan testing.  Med Mycol. 2006;  44 (Suppl) 179-183
• 47 Hope W W, Petraitis V, Petraitiene R, Aghamolla T, Bacher J, Walsh T J. The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy.  Antimicrob Agents Chemother. 2010;  54 (11) 4879-4886
• 48 Koo S, Bryar J M, Baden L R, Marty F M. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis.  J Clin Microbiol. 2010;  48 (4) 1255-1260
• 49 Maertens J, Maertens V, Theunissen K et al.. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases.  Clin Infect Dis. 2009;  49 (11) 1688-1693
• 50 Odabasi Z, Mattiuzzi G, Estey E et al.. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome.  Clin Infect Dis. 2004;  39 (2) 199-205
• 51 Obayashi T, Yoshida M, Mori T et al.. Plasma (1—>3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes.  Lancet. 1995;  345 (8941) 17-20
• 52 Donnelly J P. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go.  Clin Infect Dis. 2006;  42 (4) 487-489
• 53 Herbrecht R, Denning D W, Patterson T F Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.  N Engl J Med. 2002;  347 (6) 408-415
• 54 Alvarez-Lerma F, Allepuz-Palau A, Garcia M P Voriconazole Study Group in Critically Ill Patients et al. Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function.  J Chemother. 2008;  20 (1) 93-100
• 55 Eiden C, Peyrière H, Cociglio M Network of the French Pharmacovigilance Centers et al. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database.  Ann Pharmacother. 2007;  41 (5) 755-763
• 56 Steinbach W J, Stevens D A. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis.  Clin Infect Dis. 2003;  37 (Suppl 3) S157-S187
• 57 Thompson III G R, Rinaldi M G, Pennick G, Dorsey S A, Patterson T F, Lewis II J S. Posaconazole therapeutic drug monitoring: a reference laboratory experience.  Antimicrob Agents Chemother. 2009;  53 (5) 2223-2224
• 58 Ullmann A J, Lipton J H, Vesole D H et al.. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.  N Engl J Med. 2007;  356 (4) 335-347
• 59 Cornely O A, Maertens J, Winston D J et al.. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.  N Engl J Med. 2007;  356 (4) 348-359
• 60 Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.  Br J Clin Pharmacol. 2004;  57 (2) 218-222
• 61 De Beule K, Van Gestel J. Pharmacology of itraconazole.  Drugs. 2001;  61 (Suppl 1) 27-37
• 62 Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications.  Antimicrob Agents Chemother. 2009;  53 (1) 24-34
• 63 Bennett J E. Echinocandins for candidemia in adults without neutropenia.  N Engl J Med. 2006;  355 (11) 1154-1159
• 64 Viscoli C, Herbrecht R, Akan H Infectious Disease Group of the EORTC et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.  J Antimicrob Chemother. 2009;  64 (6) 1274-1281
• 65 Marr K A, Boeckh M, Carter R A, Kim H W, Corey L. Combination antifungal therapy for invasive aspergillosis.  Clin Infect Dis. 2004;  39 (6) 797-802
• 66 Patterson T F, Boucher H W, Herbrecht R European Organization for Research and Treatment of Cancer (EORTC) Invasive Fungal Infections Group (IFIG) et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.  Clin Infect Dis. 2005;  41 (10) 1448-1452
• 67 Bates D W, Su L, Yu D T et al.. Mortality and costs of acute renal failure associated with amphotericin B therapy.  Clin Infect Dis. 2001;  32 (5) 686-693
• 68 Cornely O A, Maertens J, Bresnik M AmBiLoad Trial Study Group et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).  Clin Infect Dis. 2007;  44 (10) 1289-1297
• 69 Winston D J, Bartoni K, Territo M C, Schiller G J. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.  Biol Blood Marrow Transplant. 2011;  17 (4) 507-515
• 70 Howard S J, Cerar D, Anderson M J et al.. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure.  Emerg Infect Dis. 2009;  15 (7) 1068-1076
• 71 Balajee S A, Gribskov J L, Hanley E, Nickle D, Marr K A. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus.  Eukaryot Cell. 2005;  4 (3) 625-632
• 72 Balajee S A, Weaver M, Imhof A, Gribskov J, Marr K A. Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals.  Antimicrob Agents Chemother. 2004;  48 (4) 1197-1203
• 73 Denning D W, Park S, Lass-Florl C et al.. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease.  Clin Infect Dis. 2011;  52 (9) 1123-1129